Stockwinners Market Radar for January 09, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST Bit Brother Ltd trading halted, news pending

19:02 EST OceanaGold names Bhuvanesh Malhotra chief technical and projects officer - OceanaGold Corporation announced the appointment of Bhuvanesh Malhotra as Chief Technical and Projects Officer, effective January 22, 2024. Gerard Bond, President and Chief Executive Officer of OceanaGold, said "I am delighted to welcome Bhuvanesh to our Executive Leadership Team. Following an extensive search, we are pleased to have attracted such a strong and accomplished technical leader to drive value in our projects and studies function during an exciting growth phase for OceanaGold."

18:04 EST Intel announces agreement to acquire Silicon Mobility, terms not disclosed - At CES, Intel announced plans to drive the company's AI everywhere strategy into the automotive market, including a deal to acquire Silicon Mobility, a fabless silicon and software company that specializes in SoCs for intelligent electric vehicle energy management. Intel also announced: a new family of AI-enhanced software-defined vehicle system-on-chips, with Zeekr as the first original equipment manufacturer to adopt the new SoC to deliver its generative AI-driven living room experiences to next-generation vehicles. The acquisition is subject to necessary approvals.

17:51 EST Shares of Cameco, NexGen Energy spike after U.S. DOE call for uranium - Shares of companies in the exploration for, mining, and milling, purchase, of uranium including Cameco (CCJ), NexGen Energy (NXE), Uranium Energy (UEC), Energy Fuels (UUUU) and Ur-Energy (URG) spiked higher on Tuesday after the the U.S. Department of Energy or DOE, issued a request for proposals or RFP for uranium enrichment services to help establish a reliable domestic supply of fuels using high-assay low-enriched uranium or HALEU, a crucial material needed to deploy advanced nuclear reactors, which will help reach President Biden's goal of net-zero emissions by 2050, increase energy security, create good-paying jobs, and strengthen U.S. economic competitiveness. Reference Link

17:46 EST HP Enterprise to acquire Juniper for $40.00 per share in cash, or EV $14B

17:36 EST Walmart offers drone delivery for up to 75% of DFW population - Walmart said it is offering drone delivery for up to 75% of the Dallas-Fort Worth population. "This expansion will bring the ultimate convenience of drone delivery to communities across the DFW area. Customers will have access to a broad assortment of items from Walmart available for delivery to their home in just minutes," said Prathibha Rajashekhar, senior vice president, Innovation & Automation, Walmart U.S. "Drone delivery is not just a concept of the future, it's happening now and will soon be a reality for millions of additional Texans." The drone delivery expansion includes stores across more than 30 towns and municipalities in the DFW metroplex, marking the first time a U.S. retailer has offered drone delivery to this many households in a single market. The deliveries will be powered by on-demand drone delivery providers, Wing and Zipline. Both are approved by the FAA to fly their drones without a dedicated observer being able to see the drone at all times, known as Beyond Visual Line of Sight, Walmart said. Reference Link

17:33 EST Lennar increases stock repurchase program by $5B - Lennar also announced that its board of directors has authorized an increase to the company's stock repurchase program to enable the company to repurchase up to an additional $5B in value of its outstanding Class A or Class B common stock. Repurchases are authorized to be made in open-market or private transactions. The repurchase authorization has no expiration date.

17:16 EST Lockheed Martin awarded $101.51M Navy contract - Lockheed Martin was awarded a $101.51M cost-plus-incentive-fee and cost-plus-fixed-fee contract for AEGIS development and test sites operation and maintenance. This contract contains options which, if exercised, would bring the cumulative value of this contract to $462.44M. Work will be performed in Moorestown, New Jersey and is expected to be completed by January 2028. This contract was not competitively procured in accordance with 10 U.S. Code 3204. Naval Sea Systems Command is the contracting activity.

17:14 EST Key Tronic CEO Craig Gates to retire, Brett Larsen to succeed on June 30 - Key Tronic announced that effective June 30, its Board of Directors has named Brett Larsen to succeed Craig Gates as the company's President and CEO. Gates will retire from the company effective June 30, but expects to remain a member of the company's Board of Directors. Larsen, who has served as the company's Executive Vice President of Administration, CFO, and Treasurer since July 2015, joined the company in May 2004 and has assumed ever-increasing roles and responsibilities over the past 20 years. Tony Voorhees will also be promoted to Executive Vice President of Administration, CFO, and Treasurer on June 30. In addition, Patrick Sweeney retired from the Board and his role as Chairman on January 4. In his stead, the Board has nominated director Ronald Klawitter to act as Chairman until the next Annual Meeting of the Shareholders. In addition, the Board welcomed Cheryl Berenak, founding member and CEO of Clearfield Communications, to the Board on January 4.

17:09 EST Blueprint Medicines says AYVAKIT has potential to be multibillion-dollar therapy - During the J.P. Morgan conference presentation yesterday, Blueprint Medicines CEO Kate Haviland stated: "As we enter 2024, AYVAKIT's early launch success in indolent systemic mastocytosis has grown our conviction that AYVAKIT has the potential to be a multi-billion-dollar therapy that will drive long-term growth into the next decade. We know that the first few quarters of a launch are critical in defining the trajectory of a new medicine, and we have built a strong foundation for success with AYVAKIT as we continue to drive growth in the U.S. and expand our launch in Europe this year. Throughout 2023, we also made significant progress across our research and development pipeline enabling us to focus investments on our most promising programs. A core component of our growth strategy is to build on our leadership position in SM by expanding to other allergic-inflammatory diseases where mast cells play a core role in the biology, and we have integrated infrastructure that we can efficiently scale. Across our portfolio, we are investing in our most compelling opportunities to deliver innovative, life-changing medicines to patients, while maintaining a strong and sustainable financial profile."

17:06 EST West Fraser Timber to close sawmill in Maxville, expects $50M in charges - West Fraser Timber announced that it will close its sawmill in Maxville, Florida and indefinitely curtail operations at its sawmill in Huttig, Arkansas by the end of this month. Today's decision is the result of high fiber costs and soft lumber markets. The closure of Maxville Sawmill will impact approximately 80 employees, while the indefinite curtailment of Huttig will impact 140 employees. In aggregate this will reduce West Fraser's U.S. lumber capacity by approximately 270M board feet. West Fraser expects to mitigate the impact on affected employees by providing work opportunities at other company operations. High fiber costs at Maxville and the current low-price commodity environment have impaired the ability of both mills to profitably operate. The closure of Maxville and the indefinite curtailment of the Huttig sawmill better aligns our U.S. lumber capacity with demand. West Fraser anticipates taking restructuring and impairment charges of approximately $50M in the Q4 associated with this announcement.

17:01 EST Luminar, Mercedes-Benz expand partnership to Formula 1 - Leading global automotive technology company Luminar (LAZR) and the Mercedes (DDAIF)-AMG PETRONAS F1 Team announced a new strategic collaboration that will leverage Luminar's existing development work with Mercedes-Benz to integrate Luminar's technology into the Official FIA F1 Safety Car with that work beginning in 2024. LiDAR, which stands for Light and Detection Ranging, uses lasers to create a highly detailed 3D map of the surrounding environment. Luminar's LiDAR coupled with its AI software uniquely enables precise object detection at higher speeds and under adverse driving conditions. Luminar's technology is built from the chip-level up, and at a higher wavelength that allows it to see road debris up to 250 meters and objects up to 500 meters ahead. The ability to detect still and moving objects at high speeds and under wide ranging conditions make Luminar's LiDAR an excellent match for the Official FIA F1(R) Safety Car. Luminar and Mercedes-AMG will work together to integrate Luminar's technology into the roofline of the Mercedes-AMG GT Black Series.

16:42 EST PriceSmart jumps 8% to $78.75 after Q1 results

16:32 EST Nasdaq notifies Mesa Air 'not' in compliance due to filing delay of 10K - Mesa Air Group announced that it received a notice on January 4, from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company failed to timely file its Annual Report on Form 10-K for the period ended September 30, 2023 with the Securities and Exchange Commission. The filing delay is not the result of a forthcoming restatement of the Company's financial statements or any disagreement with the Company's auditors.

16:31 EST Valaris announces new contracts, extensions with associated backlog of $1.14B - Valaris Limited announced new contracts and contract extensions, with associated contract backlog of approximately $1.14B, awarded subsequent to issuing the company's most recent fleet status report on November 1, 2023. Contract backlog excludes lump sum payments such as mobilization fees and capital reimbursements. President and Chief Executive Officer Anton Dibowitz said, "We are delighted to announce these contract awards and extensions, which add well over $1 billion of contract backlog at attractive economics, providing further evidence of the positive outlook for Valaris. These awards include two multi-year drillship contracts and several jackup contracts across the North Sea, Trinidad, and Australia."

16:27 EST Gatos: CLG mine Q4 average mill throughput 3,000 tonnes per day plus - Gatos Silver announced production results for the quarter and year ended December 31, 2023 at its 70%-owned Cerro Los Gatos mine in Mexico. Silver production and silver equivalent production were both near the top end of the 2023 guidance range, even after taking into account an upward guidance revision in November 2023. Dale Andres, CEO of Gatos Silver, commented: "The CLG mine performed very well during the fourth quarter and full year 2023. The operation achieved another record for mill throughput, with a quarterly average higher than 3,000 tonnes per day during the fourth quarter. This was the fourth consecutive quarterly increase in mill throughput rate, partially offsetting the expected lower grades of ore mined in 2023 compared with 2022. We are very encouraged by recent mill throughput tests, which indicate that 3,500 tonnes per day is possible without significant capital investment. We are also continuing to evaluate mill expansion options up to 4,000 tonnes per day in conjunction with further mine life extension opportunities." Silver equivalent production is calculated using prices of US$22/oz silver, US$1.20/lb zinc, US$0.90/lb lead and US$1,700/oz gold to "convert" zinc, lead and gold production contained in concentrate to "equivalent" silver ounces...Due to the continued strong performance of CLG during 2023 and changes to mine plan sequencing, Gatos Silver increased production guidance for silver and silver equivalent on November 6 from the original levels provided on February 23 Production guidance for zinc, lead and gold did not change after February 23, 2023. Gatos Silver expects to provide annual production and cost guidance for 2024 toward the end of February....silver production of 9.21M ounces and silver equivalent production of 14.33 M ounces were both close to the high end of upwardly revised guidance. For metals with no guidance change during 2023, lead production of 38.9M pounds was close to the high end of guidance, zinc production of 57.3M pounds was slightly higher than the low end of guidance, and gold production was slightly below guidance.

16:21 EST Astronics up2% at $15.90 after Q4 revenue pre-announcement, initial FY24 outlook

16:18 EST SVB Capital: SVB Financial Group will retain ownership of the business - SVB Capital Management, a wholly-owned indirect subsidiary of SVB Financial Group, announced that, following a review of strategic alternatives, SVB Financial Group and its creditors have determined that retaining the SVB Capital business would result in superior value creation opportunities. In connection with mapping its go-forward strategy, SVB Capital has created a new operating committee that will oversee all aspects of the business' strategic and operational initiatives. The operating committee is made up of Aaron Gershenberg, Sulu Mamdani and Beau Laskey, three longtime SVB Capital executives and experienced venture capital leaders. Gershenberg, a co-founder of SVB Capital who has served as a Senior Advisor since January 2023, is returning as a Managing Partner. The operating committee will be focused on maximizing the value of SVB Capital's portfolio and assets and continuing to serve its limited partners. The committee will work closely with William Kosturos, Chief Restructuring Officer of SVB Financial Group, to ensure a smooth transition.

16:16 EST KeyCorp names Darrin Benhart as Chief Risk Officer - KeyCorp announced that Darrin Benhart, Deputy Chief Risk Officer, has been named the bank's Chief Risk Officer, effective January 1. Darrin succeeds Mark Midkiff, whose long-planned retirement was announced in November and who will remain at the bank through a transition period. Darrin joined Key in July 2022, after a 30-year career at the Comptroller of the Currency, U.S. Department of the Treasury, where he held a series of increasingly senior roles, including serving as Deputy Comptroller of the Currency.

16:12 EST Credo Technology names Kate Schuelke as New Chief Legal Officer - Credo Technology (CRDO) announced that Kate Schuelke will join Credo as Chief Legal Officer and Corporate Secretary on January 26, 2024. Ms. Schuelke brings more than 30 years of legal technology industry experience to Credo, having most recently served as CLO of Seagate Technology LLC where she oversaw all legal functions, including the global security and government relations teams.

16:10 EST SGH board approves $75M share repurchase authorization - On January 8, 2024, the Audit Committee of the Board of Directors approved a $75 million share repurchase authorization, bringing total share repurchase authorizations over the last two years to $150 million. Under the share repurchase authorization, the Company may repurchase its outstanding ordinary shares from time to time through open market purchases, privately-negotiated transactions or otherwise. The share repurchase authorization has no expiration date, may be suspended or terminated by the Audit Committee at any time and does not obligate the Company to acquire any amount of ordinary shares.

16:09 EST NN reports $62.6M in new business wins in 2023 - NN reports a record-breaking 2023, with $62.6M in new business wins. "Ending with a strong second half, this acceleration in new business awards is a direct result of the company's new transformational business strategy. NN continues to gain traction with wins in desirable and diversified markets through better focus, targeting and harnessing its collective strengths."Part of our transformation plan is to improve how we engage our customers and the marketplace. Our new business wins in 2023 are validation that its working and that's great news," said Harold Bevis, CEO of NN, Inc. "This opens the door for our team to partner with customers and suppliers to create unique and breakthrough value-added solutions. We are capitalizing on our highly technical process capabilities, our existing footprint and know-how. The goal is to win business, grow sales and profits." NN's pipeline of new business opportunities entering 2024 is focused and approximately $500 million in size. NN is continuing to evolve and strengthen its growth programs by focusing on specific product applications including electric steering systems, electrical systems, braking systems, electricity distribution, battery management, fluid management, EV charging systems and medical components. These are natural markets for NN's focus on precision engineered metal products and in-house proprietary tool design," said the company.

16:08 EST Terreno Realty says operating portfolio 98.5% leased at December 31, 2023 - As of December 31, 2023, Terreno Realty Corporation owned 259 buildings aggregating approximately 16.0 million square feet and 45 improved land parcels consisting of approximately 152.4 acres: The operating portfolio was 98.5% leased at December 31, 2023 to 580 tenants as compared to 98.3% at September 30, 2023 and 98.6% at December 31, 2022; The same-store portfolio of approximately 13.1 million square feet was 98.5% leased at December 31, 2023 as compared to 98.7% at September 30, 2023 and 98.8% at December 31, 2022; The improved land portfolio of 45 parcels totaling approximately 152.4 acres was 94.6% leased at December 31, 2023 as compared to 96.3% at September 30, 2023 and 92.5% at December 31, 2022; Cash rents on new and renewed leases totaling approximately 0.3 million square feet and 0.0 acres of improved land commencing during the fourth quarter increased approximately 47.5% with a tenant retention ratio of 75.6% for the operating portfolio and 0.0% for the improved land portfolio. Cash rents on new and renewed leases totaling approximately 2.1 million square feet and 11.4 acres of improved land commencing during the year ended December 31, 2023 increased approximately 55.5% with a tenant retention ratio of 57.7% for the operating portfolio and 16.8% for the improved land portfolio; and Terreno Realty Corporation completed the development of Countyline Corporate Park Phase IV Building 41 in Hialeah, Florida and leased 100% of the building to an international logistics services provider. Building 41 of Terreno Realty Corporation's Countyline Corporate Park is a 191,000 square foot 32-foot clear height rear-load industrial distribution building on 10.5 acres with 62 dock-high and two grade-level loading positions and parking for 196 cars. The building is expected to achieve LEED certification, the total expected investment is $41.2 million and the estimated stabilized cap rate is 5.1%.

16:07 EST Zillow Group reappoints Bill Gurley to Board of Directors - Zillow Group announced the reappointment of Bill Gurley, prominent venture capitalist and partner at Benchmark Capital, to the company's Board of Directors, effective immediately. Gurley previously served on the Board from 2005 to 2015.

16:06 EST PriceSmart reports Q1 comparable net merchandise sales up 8% - Comparable net merchandise sales for the 50 warehouse clubs that have been open for greater than 13 1/2 calendar months increased 8.0% for the 13-week period ended December 3, 2023 compared to the comparable 13-week period of the prior year. Comparable net merchandise sales - constant currency for the 13 weeks ended December 3, 2023 increased 4.3%. Foreign currency exchange rate fluctuations impacted comparable net merchandise sales positively by 3.7% versus the same period in the prior year.

16:05 EST Sonos names Saori Casey CFO - Sonos announced that industry leading corporate finance executive Saori Casey will join the company's executive leadership team as its new Chief Financial Officer, effective January 22, 2024. Saori will oversee all financial, accounting, real estate, technology, and investor relations functions within the company. Saori succeeds current CFO Eddie Lazarus, who will take on the new role of Chief Strategy Officer while retaining existing duties as Chief Legal Officer. Saori brings more than 30 years of corporate finance experience, with nearly 13 years serving as Vice President of Finance at Apple, where she was responsible for running all aspects of Apple's financial planning, forecasting, capital allocations, investor relations, as well as financial management of all G&A functions. Prior to joining Apple, Saori spent 15 years at Cisco, where she held a number of finance leadership roles spanning operations, sales, R&D, FP&A, M&A, and systems, as the company scaled its revenue from $4 billion to over $40 billion. In addition, Saori serves on the board of Houzz, as both chair of the Audit Committee and a member of the Compensation Committee. "I am excited to welcome Saori as our new CFO. The depth and breadth of her experience at world-class companies like Apple and Cisco make her perfectly suited to build on our momentum and seize the opportunity ahead," says Sonos CEO Patrick Spence. "Saori's appointment to CFO and Eddie's transition to Chief Legal and Strategy Officer, along with the recent appointments of Deirdre Findlay as Chief Commercial Officer and Maxime Bouvat-Merlin as Chief Product Officer, have yielded an accomplished executive leadership team poised to accomplish our ambition to be the world's leading sound experience company."

15:57 EST U.S. looks to increase production of higher-energy uranium, DOE says - In support of President Biden's Investing in America agenda, the U.S. Department of Energy or DOE, issued a request for proposals or RFP for uranium enrichment services to help establish a reliable domestic supply of fuels using high-assay low-enriched uranium or HALEU, a crucial material needed to deploy advanced nuclear reactors, which will help reach President Biden's goal of net-zero emissions by 2050, increase energy security, create good-paying jobs, and strengthen U.S. economic competitiveness. The DOE, continued in part : "Currently, HALEU is not commercially available from U.S.-based suppliers, and boosting domestic supply could spur the development and deployment of advanced reactors in the United States. .."The Biden-Harris Administration knows that nuclear energy is essential to accelerating America's clean energy future," said Assistant to the President and National Climate Advisor Ali Zaidi."... It's good news for our economy, for America's union workforce, and for our planet." In total, President Biden's Inflation Reduction Act will provide up to $500M for HALEU enrichment contracts selected through this RFP and a separate one, released in November, for services to deconvert the uranium enriched through this RFP into metal, oxide, and other forms to be used as fuel for advanced reactors...most U.S. advanced reactors require HALEU, which is enriched between 5% to 20%, to achieve smaller and more versatile designs with the highest standards of safety, security, and nonproliferation.... DOE's Office of Nuclear Energy plans to award one or more contracts to produce HALEU from domestic uranium enrichment capabilities. Once enriched, the HALEU material will be stored on site until there is a need to ship it to deconverters... Together, the United States, Canada, France, Japan, and the United Kingdom have announced collective plans to mobilize $4.2B in government-led spending to develop safe and secure nuclear energy supply chains." Companies in the space include: Cameco (CCJ), NexGen Energy (NXE), Uranium Energy (UEC), Energy Fuels (UUUU) and Ur-Energy (URG). Reference Link

15:34 EST Nocera COO Hong-Wen Ruan to retire, Feng-Hua Chen to succeed - Nocera announced that the company's current COO, Hong-Wen (Howard) Ruan has decided to retire effective as of January 4. Feng-Hua (Howard) Chen has been appointed as the company's new COO, effective immediately. Chen will manage all aspects of Nocera's operations as the company continues to execute its strategic vision of creating an environmentally friendly sustainable seafood company. Chen joins Nocera with over 30 years of executive level experience in the fields of financial services, construction, sales and business development.

15:13 EST FAA says every Boeing 737-9 Max with plug door will remain grounded for now - The FAA issued the following update on the grounding of Boeing 737 MAX 9 aircraft: "Every Boeing 737-9 Max with a plug door will remain grounded until the FAA finds each can safely return to operation. To begin this process, Boeing must provide instructions to operators for inspections and maintenance. Boeing offered an initial version of instructions yesterday which they are now revising because of feedback received in response. Upon receiving the revised version of instructions from Boeing the FAA will conduct a thorough review. The safety of the flying public, not speed, will determine the timeline for returning the Boeing 737-9 Max to service." Reference Link

14:53 EST Google and Samsung blend Nearby Share and Quick Share in cross-Android solution - Sameer Samat GM and VP of Android Ecosystem said in part, ealier on the The Keyword blog: "Android (GOOG, GOOGL) is all about giving you the ability to choose the devices that work best for you and making sure they connect seamlessly together, regardless of what brand they are...and at CES, we're announcing updates to help you get more done across your phone, laptop, Bluetooth accessories, TV, smart home and car... In 2020, we introduced Nearby Share to make it easy to share files across devices. Samsung (SSNLF), also has its own capability called Quick Share, which is loved by their users. Collaborating with Samsung we're bringing the best of our sharing solutions together into a singular cross-Android solution under the Quick Share name. We've integrated the experiences and created the best default, built-in option for peer-to-peer content sharing across all types of devices in the Android and Chromebook ecosystems. And to make sharing even more seamless between devices, we're working with leading PC manufacturers like LG to expand Quick Share to Windows PCs as a pre-installed app.This means with a simple tap of the new Quick Share icon, you can see a list of available devices close by. You remain in control of your privacy, and can choose in your phone's settings who can discover your device and send files, whether it's everyone, only your contacts or just your own devices. Quick Share will start rolling out to current Nearby Share enabled devices next month...And to make sharing even more seamless between devices, we're working with leading PC manufacturers like LG to expand Quick Share to Windows (MSFT) PCs as a pre-installed app." Reference Link

14:29 EST FAA says every Boeing 737-9 MAX with plug door to remain grounded for now - The FAA says it will conduct a review after getting revised instructions from Boeing and that every 737-9 MAX with a plug door will remain grounded for now, according to Bloomberg.

14:13 EST Honda to launch '0 Series' EV model in North America in 2026 - Honda announced the "Honda 0 Series," a new global EV series launching in 2026, represented by the world premiere of two concept models, Saloon and Space-Hub, at CES 2024. "In 2026, Honda will introduce a model of the Honda 0 Series based on the Saloon concept in North America, followed by model introductions in Japan, Asia, Europe, Africa and the Middle East and South America... Honda also debuted a new H mark logo that will be used exclusively for the next-generation EV models," the company announced. Reference Link

13:35 EST Mobileye expands collaboration with M&M to explore next-gen driving systems - Mobileye is expanding its existing relationship with Mahindra & Mahindra or M&M, "a leader in automotive, farm and services businesses." Mobileye will collaborate with M&M to introduce multiple solutions based on Mobileye's next-generation EyeQ 6 systems-on-chip and sensing and mapping software, including an intent to build a full-stack autonomous driving system. Mobileye will leverage its extensive portfolio of advanced solutions and expertise in autonomous driving technologies to develop higher degrees of ADAS levels to be introduced on M&M's upcoming platforms. This includes a collaboration for next generation driving assistance features based on Mobileye's SuperVision platform, and for deploying new mapping solutions. This step is in line with Mahindra's commitment to deliver market-leading, innovative solutions that enhance safety, comfort and driving experience for their customers and also enhance the supply chain resiliency of related components for M&M. This collaboration strengthens the existing relationship between M&M and Mobileye, which resulted in the introduction of a segment-first suite of ADAS features in India on the Mahindra XUV7OO in 2021, setting the stage for future innovations in active safety. Reference Link

13:02 EST Alibaba.com announces AI-powered Smart Assistant launch - Alibaba.com, part of Alibaba International Digital Commerce Group, or AIDC, will launch its latest Smart Assistant features powered by artificial intelligence at CES in Las Vegas, NV from January 9-12, the company announced. "The Smart Assistant, an AI-powered global sourcing tool, caters to both newcomers and seasoned entrepreneurs in the dynamic world of global commerce. As a one-stop B2B sourcing platform, Alibaba.com remains committed to delivering innovative solutions to help buyers and suppliers streamline operations to more efficiently reach their goals and continue to grow. The Smart Assistant updates unveiled at CES will help business owners adeptly enhance their supply chain and solve complex sourcing needs and challenges as they seek to stand out in today's competitive marketplace," the company stated. Chris Lu, General Manager at Alibaba.com North America, added: "With advances in AI, we are ushering in the next generation of sourcing and empowering small businesses to succeed with our Smart Assistant at their side."

12:23 EST Disney announces new 'Star Wars' film titled 'Mandalorian & Grogu' - Disney announced that "The Mandalorian & Grogu," a film spinoff in the "Star Wars" universe, will go into production in 2024. The movie, based on the "Mandalorian" Disney+ show universe, will be directed by Jon Favreau, and produced by Favreau, Kathleen Kennedy, and Dave Filoni. "I have loved telling stories set in the rich world that George Lucas created," said Favreau. "The prospect of bringing the Mandalorian and his apprentice Grogu to the big screen is extremely exciting." Reference Link

12:14 EST Cytokinetics slips after Novartis CEO says M&A focus on 'bolt ons' - Shares of Cytokinetics (CYTK) have dropped during midday trading after Novartis' (NVS) CEO Vasant Narasimhan was asked by CNBC's Jim Cramer to comment if the company was interested in buying Cytokinetics, as had been reported yesterday afternoon by The Wall Street Journal. Narasimhan declined to comment on any specific potential deals, but said the company is focused on bolt-on acquisitions. "Our overall M&A strategy... is really to focus on sub $5 billion assets... Now we look at larger deals, which is why I think you see the media coverage, it's always something that we do and we have an obligation to do that, but what I really want to highlight is that while we look at larger deals, our M&A strategy is bolt ons," Novartis' CEO said during the earlier interview on CNBC. A bit after noon in New York, Cytokinetics shares are down $9.84, or 9%, to $98.22. Reference Link

12:00 EST HP Enterprise falls -7.4% - HP Enterprise is down -7.4%, or -$1.31 to $16.41.

12:00 EST Mativ falls -8.3% - Mativ is down -8.3%, or -$1.24 to $13.73.

12:00 EST Vince Holding rises 16.9% - Vince Holding is up 16.9%, or 59c to $4.08.

11:40 EST Accenture agrees to acquire Work & Co; terms not disclosed - Accenture has agreed to acquire Work & Co, a global digital product company that "blends design, technology, and innovation to help companies create breakthrough products and experiences." Headquartered in New York, Work & Co's nearly 400 employees across the United States, Europe, and Latin America will join Accenture Song. Terms of the transaction were not disclosed. Completion of the acquisition is subject to customary closing conditions.

11:07 EST Mountain Crest Acquisition Corp IV trading resumes

11:04 EST Boeing reports 371 airplane gross orders, 67 commercial deliveries in December - In its commercial aircraft operations, Boeing reports 371 airplane gross orders and 67 commercial deliveries in December, according to data posted to its corporate website. Boeing reports 1,576 year-to-date net orders, 1,314 year-to-date orders net of cancellations/conversions and 6,216 unfilled airplane orders as of December 31, 2023. Reference Link

11:01 EST Becton Dickinson sees shifting of $30M of flu testing revenue from Q1 - The company said the quarter's sales growth played out as expected, "other than one dynamic with respect to the timing of the respiratory season." For the full year, the company continues to expect a normal sized flu season, but does see a timing shift which translates to the movement of approximately $30M of flu testing revenue from fiscal Q1 to the remainder of the year.

10:24 EST Meta to restrict teen Instagram, Facebook accounts from seeing certain content - Meta announced that it will start to hide more types of content for teens on Instagram and Facebook, in line with expert guidance, including self-harm and eating disorder content. The company said it is automatically placing all teens into the most restrictive content control settings on Instagram and Facebook and restricting additional terms in Search on Instagram and is prompting teens to update their privacy settings on Instagram in a single tap with new notifications. "We want teens to have safe, age-appropriate experiences on our apps. We've developed more than 30 tools and resources to support teens and their parents, and we've spent over a decade developing policies and technology to address content that breaks our rules or could be seen as sensitive." Reference Link

10:06 EST Wheels Up, 5x5 Trading enter three-year services agreement - 5x5 Trading announced the launch of its aircraft brokerage and advisory business and signed a three-year strategic services agreement with Wheels Up. 5x5 Trading was founded by former leaders of the Wheels Up aircraft sales division, John Odegard, Seth Zlotkin and Chris Brenner, as well as seasoned aircraft management and sales leader, Jeremy Bogle. As part of the strategic services agreement, 5x5 Trading will be the exclusive provider of acquisition and disposition services for Wheels Up, provide expertise and input on fleet planning requirements, and support Wheels Up and Air Partner members and customers on aircraft transactions.

10:03 EST Alkami enters partnership with Chimney - Alkami Technology has partnered with Chimney. Through this strategic partnership, financial institutions can empower homeowners with the financial tools, data, and insights they need to manage their greatest financial asset within digital banking. Chimney provides homeowners with actionable advice about their home value, home equity, borrowing power, and personalized offers - regardless of which financial institution holds their mortgage. Until now, many financial institutions have relied on manual methods of activating property data, which restricted their ability to personalize loan offers and engage homeowners, who often leverage third-party real estate websites to track their home value and may be targeted with a competitive offer.

10:02 EST Ferguson announces acquisitions of Yorkwest Plumbing Supply, Grove Supply - Ferguson plc has signed definitive purchase agreements to acquire Yorkwest Plumbing Supply Inc. and Grove Supply, Inc., and closed on the acquisition of Harway Appliances. These acquisitions have aggregate annualized revenues of approximately $220M. Yorkwest's business operations will be integrated into Ferguson's subsidiary in Canada, Wolseley Canada. The acquisition of Harway Appliances closed on Jan. 8. The Yorkwest and Grove Supply acquisitions are expected to close in the next 90 days, subject to customary closing conditions including regulatory clearance of the Yorkwest acquisition.

10:01 EST Acuity Brands rises 7.9% - Acuity Brands is up 7.9%, or $16.21 to $220.73.

10:00 EST Aspen Aerogels falls -7.5% - Aspen Aerogels is down -7.5%, or -$1.09 to $13.41.

10:00 EST LoanDepot falls -9.4% - LoanDepot is down -9.4%, or -32c to $3.04.

09:53 EST Nubia Brand International Corp trading resumes

09:48 EST Nubia Brand International Corp trading halted, volatility trading pause

09:47 EST United States Natural Gas Fund rises 6.0% - United States Natural Gas Fund is up 6.0%, or 36c to $6.37.

09:47 EST ProShares UltraShort Bloomberg Natural Gas falls -5.9% - ProShares UltraShort Bloomberg Natural Gas is down -5.9%, or -$4.56 to $72.88.

09:47 EST LoanDepot falls -9.5% - LoanDepot is down -9.5%, or -32c to $3.04.

09:44 EST Angion Biomedica Corp trading resumes

09:34 EST Neximmune Inc trading halted, volatility trading pause

09:31 EST The Outset skincare collection launches at QVC - QVC announced that The Outset, the skincare collection founded by Scarlett Johansson and beauty expert Kate Foster, will launch live on QVC on January 9th during "Girls Night In with Courtney and Jane" at 9pm ET.

09:20 EST Kymera Therapeutics provides 2024 corporate goals - Kymera's corporate goals for 2024 include: Immunology Portfolio: Kymera is working to build an industry-leading oral immunology pipeline by leveraging its disease agnostic discovery platform, deep expertise gained through the development of its first-in-class IRAK4 program, and unique target selection strategy that focuses on genetically and clinically validated pathways, to build a portfolio of oral medicines with efficacy comparable to in-pathway biologics. Collaborate with Sanofi to complete enrollment of the KT-474/SAR444656 Phase 2 hidradenitis suppurativa and atopic dermatitis clinical trials, with topline data expected to be reported in the first half of 2025. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflammatory diseases. Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies. Kymera has an option after Phase 2 and prior to the first Phase 3 study to opt in and equally share development and commercialization costs and profits in the U.S. while retaining tiered royalties in the rest of the world. Initiate dosing in the KT-621 Phase 1 trial in the second half of 2024, with Phase 1 data expected to be reported in 2025 KT-621 has shown in preclinical studies to be a potent, oral degrader of STAT6, the only specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation in allergic diseases, with in vitro and in vivo efficacy similar or superior to dupilumab. KT-621 has potentially broad utility across a number of allergic diseases, including atopic dermatitis, asthma and chronic obstructive pulmonary disorder, among others. Complete activities to enable IND filing and initiate dosing in the KT-294 Phase 1 clinical trial in the first half of 2025, with Phase 1 data expected to be reported in 2025. KT-294 has shown in preclinical studies to be a potent oral degrader of TYK2, a member of the Janus Kinase family required for Type I interferon, IL-12 and IL-23 signaling with both genetic and clinical validation in autoimmune and inflammatory diseases. Degradation of TYK2 has the potential to overcome the challenges of small molecule inhibitors, which have limitations due to lack of selectivity, limited target engagement, and/or lack of potent activity. KT-294, with a potential biologic-like efficacy profile, has the opportunity to address conditions such as inflammatory bowel disease, psoriasis, psoriatic arthritis and lupus, among others. Oncology Portfolio: Kymera is progressing degrader programs in oncology that target undrugged or poorly drugged proteins in an effort to create new ways to fight cancer that improve the standard of care and have the potential treat both solid and liquid tumors. Complete the KT-333 Phase 1a study and deliver additional proof-of-concept data to inform the program's next development steps in 2024: KT-333 is designed as a potent degrader of STAT3, a transcriptional regulator that has been linked to numerous cancers as well as to inflammatory and autoimmune diseases. KT-333 is being developed for the treatment of STAT3-dependent hematological malignancies and solid tumors. At the American Society of Hematology annual meeting, the Company disclosed the first proof-of-concept data for single agent KT-333 anti-tumor activity in hematological malignancies as well as potential anti-tumor immuno-modulatory effects in both tumor biopsies and blood. Complete the KT-253 Phase 1a study and deliver proof-of-concept data, which will inform a patient stratification strategy for the program in 2024: KT-253 is a highly potent and selective degrader that targets MDM2, the crucial regulator of the most common tumor suppressor, p53. A Phase 1 study of KT-253 is ongoing, with one arm in patients with relapsed or refractory solid tumors and lymphomas, and a second arm focused on patients with high grade myeloid malignancies and acute lymphocytic leukemia. Interim data from the study demonstrated evidence of target engagement and p53 pathway activation, as well as initial antitumor activity and a lack of the traditional hematological toxicity seen with small molecule inhibitors. Kymera is working to develop a biomarker-based patient selection strategy for subsequent development beyond Phase 1a. Research and Platform: Continue to advance, from early discovery through preclinical development, a series of high value programs in areas of unmet need with large patient populations and target classes best suited for TPD

09:21 EST Sonoma Pharmaceuticals, NovaBay enter sales, marketing agreement - NovaBay Pharmaceuticals (NBY) and Sonoma Pharmaceuticals (SNOA) announced an agreement for the sale and marketing of Avenova-branded products by Sonoma in the European Union. The new products will combine Sonoma's existing eye product Ocudox, which has already received a Class IIB CE mark for sale in the European Union, with Avenova branding, and are expected to be marketed through Sonoma's established European distribution network. This agreement brings together NovaBay's deep knowledge of eye care reflected in its Avenova brand with Sonoma's expertise in distributing hypochlorous acid products overseas. Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay's Avenova products, which are the leading hypochlorous acid-based eye care products in the U.S. Sonoma will pay NovaBay a royalty fee based on net product sales of Ocudox by Avenova, and Sonoma will continue to market its Ocudox product in the European Union.

09:13 EST AcelRx changing its name to Talphera - AcelRx announced the rebranding of the company, with a name change to Talphera. The rebrand decision was made to reflect the company's strategy of developing and commercializing products to support advancing care to optimize outcomes in medically supervised settings, moving beyond the original focus on acute pain. Talphera will commence trading on the Nasdaq Global Market under the ticker symbol "TLPH" effective January 10. The company's lead nafamostat product candidate, Niyad, is expected to have a Premarket Approval submission to the FDA in the second half of 2024. The name Talphera was derived from "Talisman". The company's new mission at Talphera is to support healthcare providers by developing and commercializing products in medically supervised settings that deliver advances in care to patients. Talphera expects to initiate the registrational study of Niyad shortly. The study has already received central Institutional Review Board approval. The first patient is expected to be enrolled for the NEPHRO study in Q1

09:11 EST Tetra Tech announces $34M USAID single-award land/resource contract - Tetra Tech announced that the U.S. Agency for International Development or USAID has awarded the Company a $34M, single-award contract to advance sustainable economic development through improved land rights governance. Under the global USAID Integrated Land and Resource Governance II project, Tetra Tech will develop and implement land and property rights policies that protect ecosystems, catalyze private sector investments, and benefit vulnerable populations, particularly securing women's rights. Our technical specialists will conduct data-driven research, implement conflict mitigation tools, and deploy innovative technology to document land rights in rural and remote areas. Tetra Tech also will facilitate strategic partnerships to institute anticorruption reforms and develop effective systems and policies that advance equitable and resilient communities. "Establishing secure and documented property rights is essential for inclusive economic growth, environmental sustainability, and food security," said Dan Batrack, Tetra Tech Chairman and CEO. "Tetra Tech is pleased to continue supporting USAID to expand global land and resource governance systems as part of our commitment to improve 1 billion lives through our projects by 2030."

09:07 EST Matterport's 3D Property Marketing selected by The Ivy Collection - Matterport announced that The Ivy Collection, one of the UK's leading restaurant brands, selected Matterport's 3D Property Marketing solution to help customers experience its private dining spaces virtually, to streamline event planning, and maximize customer satisfaction. As part of the brand revamping its website, The Ivy Collection digitized 50 of its private dining rooms with Matterport's digital twin technology. This has allowed clients to virtually walk through the space and experience the room as it is, helping set client expectations for those unable to see the venue physically, and increasing trust among clients.

09:06 EST iAnthus enters strategic partnership with Gron Edibles - iAnthus Capital Holdings nnounces a strategic partnership to bring Gron, a woman-owned producer of handcrafted cannabis-infused edibles to the New Jersey market.The initial launch of Gron Sugar-Coated Pearl gummies is now available at all MPX-NJ locations and across dispensaries throughout New Jersey. Under this partnership, Gron will produce its full range of acclaimed edible products at the iAnthus Pleasantville, NJ facility, ensuring the highest standards of quality and safety for the customers of New Jersey. The Gron expansion strategy allows the brand's team of experts to oversee the production in New Jersey, ensuring product consistency across the highly coveted and growing cannabis market. The collaboration will see the launch of Gron wholesale operations in the state, along with overseeing a steady roll-out of new products available to New Jersey customers, while providing enhanced marketing support to amplify the position of both businesses across the state. The partnership advances expansion plans for Gron in New Jersey and establishes a hub on the East Coast for the company's future growth. Gron edibles will debut in New Jersey with the launch of Sugar-Coated Pearls, made with natural fruit flavors and infused with cannabis extract. The 10-pack of pearls are available in six flavors and a variety of unique cannabinoid ratios including, CBD, CBN, and THC that offer a wide range of effects for every consumer preference. In 2024, Gron will continue expanding its product offering with the launch of a full range of edible products specifically catering to diverse consumer preferences and tailored to the local market trends.

09:05 EST Clearwater Analytics announces two executive appointments - Clearwater Analytics appointed Shane Akeroyd as its Chief Strategy Officer - CSO - and Ann-Sophie Skjoldager Bom as the Sales Director responsible for Strategic Asset Management clients. Prior to joining Clearwater Analytics, Akeroyd was President and Global Head of Account Management at IHS Markit, led IHS Markit's team in the Asia Pacific region, and managed the firm's relationships with its largest global accounts. Prior to IHS Markit, Akeroyd held executive level positions at RBC Capital Markets and also held executive and senior level roles at TD Securities, Bear Stearns, and Bank of America. Prior to joining Clearwater, Skjoldager Bom led SimCorp's sales team in North America. Prior to that, she was head of Legal responsible for all commercial and legal negotiations in the North American market.

09:04 EST Instacart: Google Shopping ads accessible to Instacart's advertising partners - Instacart (CART) and Google (GOOG, GOOGL) announced Google Shopping ads are now accessible to Instacart's advertising partners, leveraging the company's retail media data. With this expansion, CPG partners on Instacart, including Danone's Oikos, Kraft Heinz brands: Kraft, Lunchables, Oscar Mayer, and Philadelphia, as well as Publicis Media's CPG clients can activate Google Shopping ads, powered by Instacart's first-party retail media data and closed-loop insights, to reach high-intent consumers searching on Google and get their products into consumers' hands in as fast as an hour.

09:03 EST TuneIn brings its global radio service to VIZIO smart TVs - TuneIn announced today that listeners can now stream their favorite audio content on VIZIO. The TuneIn app's complete catalog of over 90,000 global radio stations, podcasts, audiobooks and more is now available on-demand to millions of users through the app row on VIZIO Smart TVs. "As the TV is the focal point of the home, VIZIO users can continue to enhance their streaming experience by accessing music, sports, news, podcasts and more through services like TuneIn," said Seta Goldstein, Senior Director of Business Development and Partnerships at VIZIO. "We are excited to offer our users an expanded range of 90,000+ radio stations quickly and easily from their VIZIO TVs."

09:02 EST Churchill Downs announces multi-year partnership with Sports Illustrated - Churchill Downs announced a multi-year partnership between Churchill Downs Racetrack and Sports Illustrated for exclusive naming rights of a new luxury dining experience, Club SI, ahead of the historic 150th running of the Kentucky Derby on Saturday, May 4, 2024. Originally planned as the 1895 Club, Club SI is scheduled to debut on Opening Night of Derby Week and offer guests a modern, sophisticated race day experience. Club SI will debut as part of the $200 million renovated Paddock Project at Churchill Downs for the upcoming 150th Kentucky Derby and offer a new luxury equine-focused dining experience with an immersive view of the all-new Paddock and Paddock Runway giving guests unparalleled behind-the-scenes experiences. "As we approach the 150th Kentucky Derby, we are thrilled to partner with a brand as iconic as Sports Illustrated to offer guests an enhanced way to enjoy this incredible anniversary event," said Mike Anderson, President of Churchill Downs Racetrack. "Sports Illustrated shares our goal of combining exciting sports moments with upscale entertainment, and Club SI will provide the perfect space to achieve this."

09:01 EST Safe and Green Development announces strategic property monetization initiative - Safe and Green Development Corporation announces that it will strategically look to monetize its real estate holdings throughout 2024. The company has already initiated this strategy with the previously announced Contribution Agreement of Lago Vista wherein the property is valued at $11.5M as an equity interest in the development. David Villarreal, President & CEO of Safe and Green Development Corporation stated, "Over the past three years we have worked diligently to garner valuable entitlements on the land we have acquired. We will analyze certain markets to determine how we can best monetize the appreciation of the land value. We believe this strategy will enable us to align our focus with minimal dilution to our shareholder base."

08:48 EST KULR Technology reduces workforce by 15% amid streamlining efforts - KULR Technology Group has reduced its total workforce by approximately 15%. The changes come as KULR works to allocate resources to its key business priorities servicing recurring aerospace and defense contracts while also focusing on improving the profitability of its commercial customer engagements as the Company targets operational breakeven in Second Quarter 2024. KULR streamlined operations at its headquarters in San Diego, California while continuing to focus on the KULR ONE Design Solutions testing platform and scaling R&D initiatives at its existing facility in Webster, Texas, a suburb of Houston.

08:43 EST SKYX Platforms to debut smart home platforms technologies at CES - SKYX Platforms announced that SKYX will debut its patented new smart home platform technologies - including its all-in-one smart home platform - at CES 2024 opening today, January 9th through the 12th in Las Vegas. The patented, disruptive all-in-one smart platform enables new and existing homes to become smart instantly.The All-In-One Smart Platform significantly saves lives, time and cost while simplifying the process of making a smart home. The smart platform installs to the ceiling within seconds through its patented Sky ceiling plug-in outlet.

08:40 EST Sidus achieves AI and hardware contract milestones amid launch approach - Sidus Space achieves critical Artificial Intelligence, AI and hardware contract milestones as the Company prepares for the commencement of its satellite constellation scheduled for launch in March 2024 with LizzieSat-1 as part of SpaceX's Transporter-10 mission from Vandenberg Space Force Base, California. Notable recent achievements include the successful delivery of an engineering unit supporting methane detection, day-in-the-life testing for hardware, and the launch of a beta-version vessel detection platform. Additionally, the successful completion of a Critical Design Review for hardware under a NASA Phase 2 Sequential award demonstrates Sidus Space's experienced adherence to and understanding of NASA standards. Future plans include delivering FeatherBox flight units to support methane detection, delivering engineering units for continued testing under the NASA Phase 2 Sequential Award, and conducting essential ground testing of pre-processing algorithms for Near-Infrared (NIR) and Short-Wave Infrared SWIR sensors. Jeremy Allam, Vice President of AI Products at Sidus Space, emphasized the Company's commitment to innovation, stating, "These milestones underscore our dedication to cutting-edge AI technology solutions that reshape

08:39 EST LiveOne provides update for its $10M share repurchase program - LiveOne provided today certain updates for its ongoing $10M stock repurchase program. Under the stock repurchase program LiveOne's management has the discretion to buy back shares of common stock of LiveOne and/or PodcastOne. LiveOne owns ~80% of PodcastOne's outstanding common stock. Robert Ellin, Chairman and CEO of LiveOne, commented, "As previously announced, we are continuing to repurchase shares of our common stock in the open market. We strongly believe our shares are grossly undervalued and our actions are intended to maximize shareholder value. Our month-over-month increasing recurring cash flows have enabled us to retire outstanding liabilities and debt, and we believe this is the best use of our excess cash."

08:39 EST SeaStar Medical issued U.S. patent with claims covering use of SCD - SeaStar Medical Holding Corporation announces the issuance of U.S. Patent No. 11,866,730 with broad claims directed to methods of using the Selective Cytopheretic Device, SCD, to treat subjects with inflammatory conditions and to process activated leukocytes and platelets. The SCD is a first-in-class, cell-directed extracorporeal therapy that selectively targets highly active inflammatory cells to quell the inflammatory response. "This patent significantly fortifies our intellectual property portfolio and is highly supportive of our strategy to validate our technology's application across multiple high-value clinical indications in which hyperinflammation plays a role," said Eric Schlorff, CEO of SeaStar Medical. "Regardless of its source, uncontrolled hyperinflammation can lead to vital organ damage and even death. Our SCD therapy works to selectively target the most highly activated cells responsible for inflammation to bring activated cells into a reparative state. This can stop the potential damage of over-activated cells and potentially reverse the damage they cause."

08:38 EST NeuroBo Pharmaceuticals regains Nasdaq compliance - NeuroBo Pharmaceuticals announced that on January 8, it received formal notice from The Nasdaq Stock Market indicating that the company has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed.

08:37 EST Atossa Therapeutics issues letter to shareholders - Atossa Therapeutics announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company's President and Chief Executive Officer: "2023 marked another year of significant progress for Atossa. There are now four Phase 2 trials underway investigating our proprietary-endoxifen, with primary data expected from two of these trials in the second half of this year. We also initiated important research with Weill Cornell Medicine that could fundamentally transform treatment options for patients diagnosed with one of the most aggressive and deadly forms of breast cancer. Our study that is furthest along is the Phase 2 Karisma-Endoxifen trial, which reached full enrollment in November 2023... Simply put, breast density is a health crisis. Almost half of the women in the world over the age of 40 have dense breasts and this condition not only makes mammograms far less effective, but it also significantly increases the likelihood that a woman will develop breast cancer in their lifetime. Adding to the issue is the fact that there are currently no approved treatments to reduce breast density... Late last year we announced a second breast cancer prevention study, which is investigating (Z)-endoxifen in women diagnosed with Ductal Carcinoma In Situ. Participants receive six months of treatment with the intent of determining their suitability for long-term active surveillance without surgery.... In the continuum of invasive breast cancer, our mammographic breast density and DCIS trials are prevention studies. We also have two ongoing Phase 2 trials investigating (Z)-endoxifen in the neoadjuvant treatment setting, which is the window of time between the diagnosis and the primary treatment.... Our EVANGELINE study is much larger with an enrollment target of 175 patients. Another important distinction is that patients in the EVANGELINE study are being treated with a higher daily dose of (Z)-endoxifen. As we communicated last year, the study commenced with a 40mg pharmacokinetic (PK) run-in cohort...Beyond the progress made in our four ongoing Phase 2 studies this year, we also initiated important research with Weill Cornell Medicine to study the potential of inducing estrogen receptor expression in triple-negative breast cancer... As important as 2023 was for our Company, 2024 promises to be an opportunity for unparalleled progress. Fortunately, we are well positioned to take advantage of the opportunities that lie ahead... As we continue to believe that our current share price and the long-term prospects of our business present an attractive and strategic buying opportunity, the Atossa Board of Directors recently extended the share repurchase program authorization through December 31, 2024. The authorization continues to be for the purchase up to $10 million of our common stock, inclusive of purchases made in 2023."

08:36 EST Inspira Technologies to launch single-use blood oxygenation kit - Inspira Technologies announced its plan to launch a single-use disposable blood oxygenation kit, currently in development, for its INSPIRA ART medical device series. The Kit is also intended to be compatible with various other life support machines, tapping into the disposable perfusion systems market. The Kit, anticipated to be submitted for FDA authorization in 2025, is a single-use product designed for efficient blood oxygenation and carbon dioxide removal. The Kit represents a strategic move to enhance hospital budget spending by potentially reducing costs. The company is focusing on making the Kit compatible with other medical devices such as certain types of cardio-pulmonary bypass machines.

08:35 EST Akebia names Nicholas Grund as Chief Commercial Officer - Akebia Therapeutics announced the appointment of Nicholas Grund as Chief Commercial Officer. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. Prior to joining Akebia, Grund served as President of Eurofins Transplant Genomics where he steered organizational change and facilitated continuous operating efficiency improvements and revenue growth. He was also Chief Commercial Officer of AMAG Pharmaceuticals where he managed commercial activities across four business units.

08:33 EST Sellas Life Sciences receives FDA fast track designation for SLS009 - SELLAS Life Sciences announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation to SLS009, its novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory acute myeloid leukemia. The Fast Track Designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need. "Receiving Fast Track Designation for SLS009 for r/r AML, following the recent Orphan Drug Designation for the same indication, underscores the potential for SLS009 and highlights the critical unmet need for patients with AML who face a poor prognosis due to the progressive nature of the disease," said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. "The initial positive topline Phase 2a data at the 45 mg dose level demonstrate that SLS009 in combination with venetoclax and azacitidine exhibits anti-leukemic effects with a favorable safety profile in AML patients resistant to venetoclax combination therapies. Importantly, as of the last follow-up, eight of the nine patients enrolled in the 45 mg cohort were alive. The first patient enrolled in the study achieved a complete response and continues on study in the seventh month with full peripheral blood recovery. The second enrolled patient is in the sixth month of treatment, further underscoring the potential benefit of adding CDK9 inhibition to the aza/ven regimen. We have now also enrolled several patients in the ongoing 60 mg dose cohort. Our team is committed to advancing the development of SLS009 with the goal of providing effective solutions to patients in need of viable treatment options."

08:32 EST Spire names Scott Doyle COO - Spire has named Scott Doyle EVP and COO, effective January 15. Doyle most recently served as EVP, utility operations at CenterPoint Energy in Houston, Texas. Prior to this role, Scott held executive leadership positions of increasing responsibility in natural gas operations and regulatory and public affairs. Scott currently serves on the board of directors of Goodwill Industries of Houston and has previously held board positions with the American Gas Association, American Gas Foundation, Southern Gas Association, Central Indiana Corporate Partnership and the Association of Electric Companies of Texas. In addition, he serves on the Engineering Advisory Council of Texas A&M University, where he earned a bachelor's degree in civil engineering.

08:23 EST Mace Security enters exclusivity agreement with Triple4s Safety - Mace Security entered into a preliminary exclusivity agreement with Triple4s Safety for purposes of jointly developing and bringing to market a smart pepper spray device that is GPS and Bluetooth enabled and which sends out current location to emergency contacts when deployed. The device's canister will be replaceable after use and will come with a glass breaker, a quick-release keychain, and a practice water canister. The formal agreement is expected to be finalized no later than March 29, 2024. Mace and Triple4S Safety will showcase the product at CES-2024 in Las Vegas on January 9-12 at booth 61636 in the Venetian Expo Hall G. Additionally, this new product will be showcased at SHOT Show Las Vegas 2024, January 23 - 26.

08:21 EST Foresight Autonomous CEO anticipates 'successful year' in 2024 - Foresight Autonomous Holdings sent a letter to shareholders from CEO Haim Siboni, which read in part, "Looking back at the dynamic events of the past year, I am pleased to share the significant achievements we accomplished in 2023 and want to discuss our strategic shift for 2024. The past year brought volatility, but it also brought success and progress for our Company. I have complete confidence in our Company and so does our entire management team. Our conviction in the success of Foresight was demonstrated in the Company's latest round of investment, led by substantial insider participation of over $1.1 million. At the end of 2023, we made a strategic decision to refocus on strengthening client-facing initiatives in the fields of defense and industrial vehicles and reallocate resources accordingly. Throughout 2023, we achieved major milestones in our journey towards commercialization, strengthening our position as a key player in the evolving market of 3D perception solutions for semi and fully autonomous vehicles. Our strategic collaborations with leading Japanese and Chinese vehicle manufacturers, the commercialization agreement with leading defense company Elbit Systems Land Ltd., and the collaboration agreement with KONEC, a South Korean Tier one supplier for agricultural vehicles, have not only secured future potential revenues but have also paved the way for groundbreaking innovations. A key aspect of Foresight's success lies in the modularity of our software vision solutions. This business model enables us to customize 3D perception solutions and tailor them to our customers' specific needs. Whether integrating our software seamlessly with existing sensors or providing a comprehensive vision solution by combining our proprietary software with customer-requested hardware, we are at the forefront of driving innovation in the industry...As we move into 2024, we anticipate a successful year, establishing new partnerships with industry leaders and progressing further on our path towards commercialization."

08:20 EST KVH Industries expands multi-orbit hybdrid network with Eutelsat - KVH Industries (KVHI) announced a distribution partnership agreement with LEO connectivity provider Eutelsat (ETCMY) OneWeb. Under the terms of the deal, KVH will offer Eutelsat OneWeb's LEO connectivity services supporting terminals for commercial and leisure vessels via Eutelsat OneWeb's LEO satellite constellation. "Adding Eutelsat OneWeb to our hybrid portfolio helps deliver on our commitment to providing outstanding connectivity, content, and services via our KVH ONE(R) integrated multi-orbit, multi-channel solution," said Brent Bruun, KVH President and Chief Executive Officer. "Eutelsat OneWeb's LEO technology will complement, enhance, and extend our KVH ONE network's existing hybrid services and enable outstanding low-latency connectivity for mariners worldwide."

08:18 EST Sacks Parente Golf expands into Club Champion stores nationwide - Sacks Parente Golf announces the expanded availability of its premium putters in all 126 Club Champion stores nationwide. "Club Champion is the leading name in custom club fitting services. Its commitment to precision and personalized golf experiences aligns with our dedication to serving golfers of all skill levels," said Greg Campbell, Executive Chairman, Sacks Parente Golf. "The validation of our technology by such a renowned retailer reinforces our belief in the importance of delivering exceptional quality to golfers, ensuring they have access to the best equipment tailored to their individual needs." Club Champion will feature all models of SPG putters in its stores, including mallets and blades, such as the recently released Series 02 DRAC and the Series 91 Duke putter.

08:17 EST Gentex to showcase latest developments at CES - Gentex Corporation will once again showcase its latest developments in technology and innovation at this year's Consumer Electronics Show, CES. Over the past year, Gentex has initiated new R&D activities, established new collaboration agreements, expanded through strategic acquisition, and diversified its product lines. All of this and more will be demonstrated at the Gentex CES booth through interactive displays, feature-integrated vehicles, and product simulators that enable customers to experience the technology in a realistic setting. "2024 marks not only a golden milestone of 50 years in business, but also a year of groundbreaking achievements and unparalleled innovation," said Steve Downing, Gentex chief executive officer. "At this year's CES, we're showcasing new advancements in nearly every product category and providing an advanced look at PLACE, our first direct-to-consumer, smart-home sensing product."

08:17 EST CNH Industrial reduces size, realigns Senior Leadership Team - CNH announces a streamlining of its leadership structure. Effective immediately, the Company is reducing the size of and realigning the Senior Leadership Team which will henceforth be known as the Global Leadership Team. The GLT is the Company's operational decision-making body responsible for driving the performance of the Company's businesses and executing strategic priorities, serving customers around the world and providing leadership to our ~40,000 employees. This leaner structure is designed to deliver focused and accountable leadership, prioritizing the Company's Business Segments. The GLT members and their corresponding areas of accountability are as follows: Scott W. Wine, Chief Executive Officer; Oddone Incisa, Chief Financial Officer; Derek Neilson, President, Agriculture; Stefano Pampalone, President, Construction; Fritz Eichler, Chief Technology Officer; Marc Kermisch, Chief Digital and Information Officer; Scott Moran, Chief Quality and Business System Officer; Tom Verbaeten, Chief Supply Chain Officer; Kelly Manley, Chief Human Resources Officer; Kevin Barr, Senior Leadership Advisor; Roberto Russo, Chief Legal and Compliance Officer. Regional and support function leaders will now report directly into the GLT-led organizations to ensure rapid and improved customer-centric decision making. These diverse and experienced leaders will remain posted at key company sites across the globe, furthering the delivery of our strategic priorities. The elevation of Fritz Eichler to Chief Technology Officer is specifically designed to provide singular focus and leadership on the development, execution, and integration of our iron and technology platforms.

08:14 EST NGM announces new data from NGM707 trial, outlines strategies for candidates - NGM Biopharmaceuticals announced encouraging new data from an ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA. NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need. "Our priorities for 2024 center on directing our efforts and investing our resources as efficiently and effectively as possible toward select development activities that we believe have the greatest potential to deliver nearer-term impact and value creation while being fully aligned with our mission to deliver life-changing medicines for patients with significant unmet needs," said David Woodhouse, PhD, Chief Executive Officer at NGM Bio. NGM707 in Advanced Solid Tumors: Announced encouraging new findings from the Phase 1 Part 1b dose escalation cohort of the ongoing Phase 1/2 trial evaluating NGM707 in combination with pembrolizumab for the treatment of patients with advanced or metastatic solid tumors. The combination of NGM707 and pembrolizumab was generally well tolerated at all four dose levels of NGM707. The maximum tolerated dose was not reached. Eight of the 37 response-evaluable patients had MSS CRC; two of these MSS CRC patients were among the confirmed PRs, including the patient with a pathological CR, and two had SD. Anti-PD-1/L1 monotherapies have shown low or no benefit in MSS CRC patients. Aldafermin in Primary Sclerosing Cholangitis: Announced planned further development of aldafermin for the treatment of PSC, a rare liver disease that irreparably damages the bile ducts, leading to bile acid dysregulation, which, ultimately, results in serious liver damage. NGM120 in Hyperemesis Gravidarum: Announced potential development of NGM120 for the treatment of hyperemesis gravidarum, subject to the outcome of ongoing discussions with the FDA.

08:12 EST Alignment Healthcare appoints Burzacchi as COO of MSO, Wagner as CPO - Alignment Healthcare announced that Sebastian Burzacchi will join as the new chief operating officer, COO, of its management services organization, MSO, and Andreas Wagner will serve as chief people officer, CPO, effective immediately. With over 18 years of experience in operations and management, Burzacchi most recently served as executive vice president of operations for Veho Tech, where he led a team of 1,000 people, its largest team. Prior to joining Alignment, Wagner served as the chief human resources officer at Aerojet Rocketdyne.

08:11 EST Lantheus expands radiopharmaceutical oncology pipeline via agreements - Lantheus Holdings (LNTH) announced it has entered into multiple strategic agreements with Perspective Therapeutics (CATX) Under the agreements, 1) Lantheus obtains an option to exclusively license Perspective's Pb212-VMT--NET, a clinical stage alpha therapy developed for the treatment of neuroendocrine tumors, and an option to co-develop certain early stage therapeutic candidates targeting prostate cancer using Perspective's innovative lead platform technology, for an aggregate upfront payment of $28 million in cash; 2) Lantheus has agreed to purchase up to 19.9% of Perspective's outstanding shares of common stock for up to approximately $33 million, subject to completion of a qualified third party financing transaction and certain other closing conditions; and 3) Perspective intends to acquire the assets and associated lease of Lantheus' radiopharmaceutical manufacturing facility in Somerset, New Jersey for an undisclosed price. "These strategic transactions will expand our pipeline and create a pathway for impactful advancements in neuroendocrine tumors and prostate cancer," said Mary Anne Heino, Chief Executive Officer of Lantheus. "We are excited to partner with Perspective, which has developed a best-in-class alpha therapy platform for lead-based therapies, and we are particularly encouraged by the early data from VMT--NET. This potentially enables Lantheus to expand our pipeline into promising alpha therapies and further solidifies our position as the leading radiopharmaceutical-focused company."

08:09 EST Tritium offers Autocharge as software capability on RTM, PKM charger models - Tritium DCFC is now offering Autocharge as a software capability on its RTM and PKM charger models. This launch allows Tritium to further provide its customers and EV drivers with convenient and efficient options for a seamless end-to-end EV charging experience. Autocharge is currently available with the latest release software for Tritium's RTM and PKM chargers. EV drivers with compatible vehicles at charging sites where the system has been implemented by a network operator will be able to start a charging session by simply plugging in their vehicle, without the need to tap or insert a payment card. Drivers love the ease of this capability, which is a feature only available to EV drivers and which cannot be offered to drivers of combustion engine vehicles. It is also very convenient for operators of busy sites with high utilization as it removes one step of the charging process and simplifies technical complexity by removing the need for a credit card reader.

08:08 EST Gildan Activewear's former CEO 'deeply disappointed' by actions of board - Glenn Chamandy, former President and CEO and co-founder of Gildan Activewear, issued the following statement in response to the open letter to shareholders issued by the company's board of directors on January 8, 2024: "I am deeply disappointed by the actions of the Gildan board of directors. Having been at the helm of Gildan for more than two decades, I take great offence at what appears to be a premeditated effort to publicly undermine my record and, what is even worse from a corporate standpoint, is that their careless behaviour is also tarnishing the reputation of a great company. The board's self-serving motives, designed to distract from its own recklessness, have led them to lose sight of what is truly important-the best interests of the company, along with its employees, customers and shareholders. I find it particularly disheartening that the board has decided to weaponize strategic confidential information of the company for the sole purpose of entrenching itself in power, with no regard for impact on value. Contrary to what the board claims, the comprehensive long-range plan presented on October 30, 2023 showed meaningful organic growth prospects for Gildan over the next five years, and was supported by our management team." The board's unfortunate actions have resulted in a massive loss of shareholder value. This destructive course of action is counterproductive, and all efforts should be redirected at driving growth that benefits all Company stakeholders, a priority which has traditionally been at the core of Gildan's values.

08:08 EST Cogent Biosciences announces planned 2024 milestones - Cogent Biosciences highlighted the company's key 2024 milestones ahead of its presentation at J.P. Morgan's 42nd annual healthcare conference. In 2024, the Company plans to achieve the following milestones: Bezuclastinib - Systemic Mastocytosis: Present data from the complete SUMMIT Part 1 trial in patients with Non-Advanced Systemic Mastocytosis at the 2024 American Academy of Allergy, Asthma & Immunology annual conference in February; Initiate SUMMIT Part 2 in 1H 2024; Finalize, including alignment with regulators, Cogent's MS2D2, a novel patient reported outcomes tool designed to measure symptomatic severity and improvement for patients enrolled in the SUMMIT study. Complete enrollment in the registration-directed APEX Phase 2 trial in patients with Advanced Systemic Mastocytosis. Bezuclastinib - Gastrointestinal Stromal Tumors: Complete enrollment of global, randomized Phase 3 PEAK trial studying the combination of bezuclastinib and sunitinib versus sunitinib alone in imatinib-resistant GIST patients. CGT4859: Initiate Phase 1 trial of the first Cogent-discovered pipeline program, designed as a potent, selective, reversible FGFR2 inhibitor with best-in-class potential. Preclinical Pipeline: Initiate IND-enabling studies for lead candidate from potent, selective ErbB2 program, highlighted by potential best-in-class brain penetrant properties; Select lead candidate and initiate IND-enabling studies from ongoing PI3Kalpha program, designed to potently and selective target the H1047R driver mutation, which affects greater than30,000 cancer patients each year

08:07 EST Movano and ams OSRAM partner to expand Evie Ring health monitoring capabilities - Movano and ams OSRAM, a provider of technology for biometric monitoring, have collaborated to include ams OSRAMs PPG sensor solution in the Evie Ring, Movano Health's smart ring designed specifically for women. Movano Health's female-first wearable, the Evie Ring, is a personalized solution designed specifically for women that provides medical-grade data measurement of critical vitals for an on-demand understanding of overall health. ams OSRAM's complete PPG sensor solution, which consists of the Optical Front End SFH 7014c emitter and SFH 2705 detector technology coupled with the company's Analog Front End AS7057, is able to achieve an increased total radiant intensity of more than 40% over the previous generation products and its photodetector has a surface area that is significantly larger than competing products.

08:06 EST eFfector Therapeutics board approves 1-for-25 reverse stock split - eFFECTOR Therapeutics announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company's common stock. The reverse stock split will become effective at 12:01 A.M. Eastern Time, on January 12, 2024. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the existing symbol "EFTR" with the new CUSIP number 28202V207 and will begin trading on a split-adjusted basis when the market opens on January 12, 2024. The CUSIP number for eFFECTOR's publicly traded warrants will not change. The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq Capital Market. The reverse split will affect all issued and outstanding shares of eFFECTOR's common stock. At the effective time of the reverse stock split the number of shares of common stock issued and outstanding will be reduced from approximately 74.9 million shares to approximately 3.0 million shares. The total authorized number of shares of common stock will be proportionally reduced from 1,000,000,000 to 40,000,000 shares. Proportional adjustments will be made to the number of shares of common stock issuable upon exercise of the Company's outstanding stock options and warrants, as well as the applicable exercise price.

08:06 EST Landsea Homes to acquire Antares Homes for $232.2M in cash - Landsea Homes announced that it has entered into a definitive agreement to acquire Antares Homes, a Dallas-Fort Worth based homebuilder. The transaction, once completed, will expand Landsea Homes' presence in the Dallas/Fort Worth metropolitan area. Landsea Homes intends to purchase Antares Homes for $232.2M in cash, which includes repayment of an anticipated $47.2M of Antares Homes debt. The transaction is subject to customary working capital adjustments upon closing. Landsea Homes expects to fund the transaction with a combination of cash and borrowings under its revolving credit facility. The transaction has been unanimously approved by the Board of Directors for Landsea Homes, and is expected to close in early February of 2024, subject to the satisfaction of customary closing conditions. Upon closing of this transaction, Antares Homes employees are expected to become part of the Landsea Homes team.

08:05 EST Magnite launches marketplace that brings together iHeartMedia's assets - Magnite announced the launch of a first-of-its-kind marketplace that brings together iHeartMedia's broadcast radio, streaming radio and podcast assets for inclusion in omnichannel programmatic media buys, providing the reach and efficiency that advertisers are seeking from audio. The marketplace enables advertisers to transact with a data-driven approach via real-time-bidding across iHeartMedia's vast broadcast and digital audio inventory through a single activation channel. "With today's consumers spending a third of their media time with audio, expanding programmatic's access to iHeart's audio assets is imperative for the industry," said Brian Kaminsky, Chief Data Officer and President of Revenue Strategies for iHeartMedia. "Not only are we expanding what role programmatic can play for advertisers, we are also improving the efficacy of their campaigns by allowing them to use real-time data to message their audience in the most engaging way possible, in an environment of trust and interest. We're excited to expand our partnership with Magnite because they have proven expertise in programmatic and the ability to build technology fit for the unique needs of audio advertising to take its place in omnichannel."

08:04 EST Honeywell and Analog Devices partner in digitization of commercial buildings - Honeywell (HON) and Analog Devices (ADI) have entered into a Memorandum of Understanding to explore the digitization of commercial buildings by upgrading to digital connectivity technologies without replacing existing wiring, which aims to reduce cost, waste, and downtime. The strategic alliance would bring this new technology to building management systems for the first time. Digitizing building management systems will allow managers to reduce energy consumption through real-time decisions, while it will upgrade a building's network performance and security to current Internet-protocol networks without extensive costs and remodeling. Honeywell plans to adopt ADI's single-pair Ethernet and software configurable input/output solutions in its building management systems.

08:04 EST GE Vernova announces 2.4 GW order for Pattern Energy's SunZia Wind project - GE Vernova's Onshore Wind business announced a new equipment and long-term services deal with Pattern Energy to supply 674 3.6-154 wind turbines that will provide more than 2.4 gigawatts of power at the SunZia Wind project in New Mexico. SunZia Wind, which is expected to be the largest wind project in the Western Hemisphere at over 3.5 GW total project size, will bring GE Vernova's installed base with Pattern Energy in North America to approximately 4.3 GW upon completion. The order, which was received in the fourth quarter of 2023, is the largest single onshore wind turbine order ever received by GE Vernova, both in terms of quantity of turbines and gigawatts of power generation, upon completion

08:02 EST Mainz Biomed provides year-end corporate review 2023 - Mainz Biomed N.V announced a year end summary of its corporate and product development progress. Key Commercial, Product Development and Operational Highlights Included: Announced groundbreaking results from ColoFuture and eAArly DETECTclinical studies evaluating the potential to integrate portfolio of novel gene expression biomarkers into a next-generation version of ColoAlert; ColoFuture reported sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 80%; eAArly DETECT reported sensitivity for CRC of 97% with a specificity of 97% and a sensitivity for AA of 82%; Expanded international commercialization of ColoAlert; Established commercial operations in major markets including Spain, Poland, Romania, Portugal, Israel, and the UK; Launched corporate health program with Germany serving as initial market via integration into Country's BGM system; Ramped-up preparations for pivotal FDA PMA clinical trial which remains on track to commence patient enrollment in mid-2024. Presents an opportunity to achieve gold-standard status for at-home CRC screening. "This past year was an exceptional period for the Company as we executed our international commercial strategy for flagship product ColoAlert while advancing product development programs," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "The latter half of 2023 was especially exciting given the groundbreaking results from the ColoFuture and eAArly DETECT studies which reported extraordinary statistical significance for CRC lesion detection and advanced adenomas, a type of pre-cancerous polyp often attributed to this deadly disease. This outstanding outcome enables optimal trial design for the ReconAAsense pivotal FDA PMA study that if successful, will now represent disruptive innovation in self-administered CRC screening, providing the opportunity to bring to market the most advanced diagnostic tool on the market. As such, we head into 2024 with a great deal of momentum as we make final preparations for ReconAAsense, with patient enrollment targeted to commence mid-year. On the commercial front, we'll continue to expand our international footprint while strengthening our presence in established markets."

08:02 EST LivePerson names John Sabino as CEO - LivePerson has appointed John Sabino as CEO, effective January 10. Sabino will also become a member of the LivePerson Board on that date. Sabino most recently served as Chief Customer Officer of VMware from October 2021 through January 8, 2024, where he led the company's 7,000-person global Customer Experience and Success organization, growing revenue to $1.3B and overseeing customer experience for VMware's over 350,000 customers, while improving consumption and SaaS license conversions by over 50%. Previously, Sabino served as Chief Customer Officer of Splunk, a provider of cybersecurity and observability technology and as Chief Operating Officer of GE Digital. John Collins, who has served as LivePerson's Interim CEO and CFO since August 2023, will continue with the company in an expanded leadership role as Chief Financial Officer and Chief Operating Officer.

07:47 EST Dundee Precious Metals reports 2023 gold production 296.1K oz. - Reports 2023 copper production 30.5M lbs. "Our mining operations continue to deliver strong results, with Ada Tepe achieving record gold production and Chelopech achieving its annual guidance for gold and copper production," said David Rae, President and Chief Executive Officer of Dundee Precious Metals. "We also continued our track record of strong sustainability performance, ranking in the 91st percentile among mining and metals companies in the 2023 S&P Global corporate Sustainability Assessment for the third consecutive year. In December 2023, we announced the acquisition of Osino Resources, which adds the advanced stage, multi-million ounce Twin Hills project in Namibia to our portfolio, and declared a maiden Mineral Resource estimate at our Coka Rakita project in Serbia, which further positions DPM as an intermediate gold producer with a growth pipeline supported by two new high-quality gold discoveries."

07:42 EST Brookfield Asset Management announces renewal of Normal Course Issuer Bid - Brookfield Asset Management has received approval from the Toronto Stock Exchange for the renewal of its normal course issuer bid to purchase up to 34,605,494 Class A Limited Voting Shares representing approximately 10% of the public float of Brookfield Asset Management's outstanding Class A Shares. Purchases under the bid will be made on the open market through the facilities of the TSX, the New York Stock Exchange and/or alternative trading systems. The period of the normal course issuer bid will extend from January 11, 2024 to January 10, 2025, or an earlier date should Brookfield Asset Management complete its purchases. Brookfield Asset Management will pay the market price at the time of acquisition for any Class A Shares purchased or such other price as may be permitted. As at December 31, 2023, the number of Class A Shares issued and outstanding totaled 413,026,253 of which 346,054,943 shares represented the public float. In accordance with the rules of the TSX, the maximum daily purchase on the TSX under this bid will be 203,206 Class A Shares, which is 25% of 812,827. Of the 31,785,036 Class A Shares approved for purchase under Brookfield Asset Management's prior normal course issuer bid that commenced on January 11, 2023 and will expire on January 10, 2024, Brookfield Asset Management purchased 7,250,707 Class A Shares as of December 31, 2023; 822,100 Class A Shares through open market purchases on the TSX and 6,428,607 Class A Shares through open market purchases on the NYSE and/or alternative trading systems. The weighted average price that Brookfield paid per Class A Share acquired under this bid was US$33.43. Brookfield Asset Management is renewing its normal course issuer bid because it believes that, from time to time, the market price of its Class A Shares may not fully reflect the underlying value of its business and its future business prospects. Brookfield Asset Management believes that, in such circumstances, the outstanding Class A Shares represent an attractive investment for Brookfield Asset Management, since a portion of its excess cash generated on an annual basis can be invested for an attractive risk adjusted return through the issuer bid. All Class A Shares acquired by Brookfield Asset Management under this bid will be cancelled and/or purchased by a non-independent trustee pursuant to the terms of Brookfield Asset Management's long-term incentive plans. Brookfield Asset Management also announced that it has entered into an automatic purchase plan in relation to the normal course issuer bid. The automatic purchase plan allows for the purchase of Class A Shares during the term of the normal course issuer bid, subject to certain trading parameters, at times when Brookfield Asset Management ordinarily would not be active in the market due to its own internal trading black-out period, insider trading rules or otherwise. Outside of these periods, Class A Shares will be repurchased in accordance with management's discretion and in compliance with applicable law.

07:40 EST Else Nutrition launch toddler, kids products in over 150 stores of major chain - Else Nutrition announces the launch of its Toddler Organic, Toddler Omega, Vanilla Kids Shakes, and Chocolate Kids Shakes across 156 stores of a major retail chain in the Northeast and Mid-Atlantic regions, which is part of a larger international grocery group with over 2,000 stores across the United States alone. This expansion strengthens Else's presence in key U.S. markets as well as demonstrates its alignment with a retailer that has a significant global footprint.

07:39 EST SurgePays closes aqcuisition of ClearLine Mobile - SurgePays has closed the asset purchase agreement to acquire the software development and point-of-sale equipment and operations of DNR Business Solutions Inc. d/b/a ClearLine Mobile. ClearLine Mobile produces a touchscreen display, positioned by the cash register, that is integrated into the SurgePays software platform and markets SurgePays products 24/7 from a central server. SurgePays can advertise its entire suite of products and services while utilizing the POS device for transactions.

07:37 EST Applied Materials collaborates with Google to advance next-gen AR platforms - Applied Materials (AMAT) announced it is collaborating with Google (GOOGL) on advanced technologies for augmented reality. The collaboration combines Applied Materials' leadership in materials engineering with Google's platforms, products and services to create lightweight visual display systems for the next wave of AR experiences. Together, the companies aim to accelerate the development of multiple generations of products, applications and services. "Applied Materials is focused on bringing the most advanced and high-performance optical technology to create brilliant, lightweight solutions designed to enable radically new products," said Dr. Paul Meissner, Vice President and General Manager of Applied Materials' Photonics Platforms Business in the Office of the CTO. "Combining our global engineering capabilities with Google's proven platforms, products and services opens endless possibilities for future AR product categories."

07:35 EST Ascent Solar announces letter of intent to supply yearly solar array orders - Ascent Solar Technologies announced that the Company has signed a LOI with an undisclosed private company to supply future orders that are anticipated to exceed 2-5 MW total from 2027 to 2029 and 100 MW per year within the next decade. "Ascent already manufactures some of the lightest PV products on the market, all of which are an order of magnitude lighter than silicon alternatives, the primary competition for space solar," said Paul Warley, CEO of Ascent Solar Technologies. "Our innovative manufacturing processes build off a portfolio of patents and other intellectual property that allow our expert team of engineers and technicians to continuously enhance materials and products that provide value to our customers. These engineering capabilities coupled with in-house manufacturing and R&D allow our team to further optimize our capabilities into the best products for high growth market applications, whether they be for agrivoltaics, space, drones, or aviation. Most significant is our ability to scale to production volumes that some of the world's most ambitious customers require and meet the high growth demand forecasts for future solar in space application."

07:35 EST Tremor International changes name to Nexxen International - Nexxen International announced that, effective immediately, its parent Company name has changed from Tremor International Ltd. to Nexxen International Ltd. following approval by shareholders at the Company's latest Annual General Meeting on December 27, 2023. The Company's change of name to Nexxen International Ltd. is expected to take effect on NASDAQ at 9:30 a.m. ET and on AIM at 8.00 a.m. GMT on January 10, 2024. In connection with the parent Company name change, Nexxen's Ordinary shares and ADRs will begin trading under the ticker "NEXN" in both markets effective January 10, 2024. There are no changes to the Company's Ordinary share structure, ADR structure, CUSIP, ISIN, or SEDOL codes, and shareholders do not need to take any further action as a result of the Company's name or ticker changes. "The changing of our name from Tremor to Nexxen International represents an exciting next step in the rebrand we embarked upon several months ago with a mission to unite our brands, simplify our story, better highlight the holistic value proposition of our unified data-driven end-to-end platform, and more strongly position ourselves as leaders in the video, data, and CTV advertising ecosystems," said Ofer Druker, CEO of Nexxen International.

07:32 EST Precision BioSciences says two deals with TG Therapeutics have $900M potential - In exchange for global rights to azer-cel for autoimmune diseases and indications outside of cancer, Precision will receive upfront and potential near-term economics valued at $17.5 M. The upfront payment of $7.5 M will consist of cash and the purchase of 2,920,816 shares of Precision common stock by TG Therapeutics at a price of 77c per share, a 100% premium to the 30-day volume-weighted average price VWAP prior to purchase. Precision will also receive $2.5 M within 12 months, as an equity investment in Precision's common stock at 100% premium to the then 30-day VWAP prior to purchase. Upon the achievement of certain near-term clinical milestones, Precision will receive an additional $7.5M payment in cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the then current 30-day VWAP. Precision is eligible to receive up to $288 M in additional milestone payments based on the achievement of certain clinical, regulatory, and commercial milestones, in addition to high-single-digit to low-double-digit royalties on net sales..."With this deal and the Imugene oncology collaboration for azer-cel announced in August 2023, Precision has now completed two cell therapy collaborations to realize value from our allogeneic CAR T platform while enabling development of azer-cel for patients in diseases with high unmet need. These transactions are expected to extend our runway and will fund continued development of our wholly owned in vivo gene editing programs. As a result of these two accretive partnerships, Precision has received or is eligible to receive $47M in upfront and potential near-term payments and has the potential to receive more than $900M in development, regulatory and commercial milestone payments," added management.

07:24 EST Signal Gold announces diamond drill results from Goldboro Project - Signal Gold announced additional diamond drill results from the Company's growth exploration program at its Goldboro Project in Nova Scotia. The diamond drill results, comprised of 2,382 metres of drilling in 13 diamond drill holes, targeted near surface gold mineralization to the west of and along strike from the Goldboro Deposit, specifically around the past producing Dolliver Mountain Gold Mine. This drilling is part of the larger growth exploration program that has now successfully tested a 1.1-kilometre strike extent of the Goldboro Trend, including the recently announced drill results that discovered gold mineralization up to 450 metres to the west of previous resource definition drilling. "We continue to be pleased with the results of diamond drilling to the west and along strike from the Goldboro Deposit. The initial drilling at Dolliver Mountain has successfully intersected gold mineralization along a 200-metre strike extent and has now confirmed that the Goldboro mineralized system extends over one kilometre to the west of the Goldboro Deposit. These results also suggest significant potential in the down-plunge eastern projection beneath the Goldboro Deposit at depths greater than 550 vertical metres, in addition to immediate potential along strike to the east and west. We continue to demonstrate the potential scale of the Goldboro Deposit, with mineralization now outlined over a strike length of at least 3.4-kilometres, with further drill results pending that targeted the remaining strike extent between Dolliver Mountain and the Goldboro Deposit," said Kevin Bullock, President and CEO, Signal Gold. The most recent drill results from 13 diamond drill holes included seven instances of visible gold and 40 separate intersections of gold mineralization that are hosted within the same anticline which hosts the Goldboro Deposit. Selected composited highlights from the current drill holes include: 7.4 g/t gold over 1.1 metres in hole BR-23-412 including, 13.01 g/t gold over 0.6 metres; 12.73 g/t gold over 0.6 metres in hole BR-23-409; 10.02 g/t gold over 0.5 metres in hole BR-23-417; and 0.61 g/t gold over 6.0 metres in hole BR-23-410. The initial drilling at Dolliver Mountain has demonstrated that, similar to the Goldboro Deposit, gold mineralization is hosted within multiple stacked argillite and quartz vein zones that are folded into an upright anticline that plunges gently to the east. Gold mineralization is associated with increased alteration including pyrite and arsenopyrite, resulting in the Induced Polarization chargeability high targeted during the current drill program. Drilling tested the host anticline to a vertical depth of 185 metres, and mineralization continues to be open to the west, east, and at depth. The intersection of gold mineralization at Dolliver Mountain also significantly demonstrates the potential for further discovery of gold down-plunge and beneath the Goldboro Deposit below 550 vertical metres. Assays are pending for an additional 19 drill holes totaling 3,813 metres from the growth exploration drill program, which are expected to be reported early in the first quarter of 2024.

07:23 EST Precision BioSciences to get $47M in near term from TG Therapeutics deal - Precision BioSciences (DTIL) announced completion of a strategic transaction with TG Therapeutics ( TGTX) for an exclusive license to develop Azercabtagene Zapreleucel, azer-ce, for autoimmune diseases, and other indications outside of cancer. "We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases. ..said Michael Amoroso, President and Chief Executive Officer at Precision BioSciences. "As TG Therapeutics assumes development of azer-cel for immunology, Precision will remain focused on capitalizing on the utility of ARCUS for gene elimination and gene insertion, beginning with our wholly owned PBGENE-HBV program for chronic hepatitis B and PBGENE-PMM for primary mitochondrial myopathy."...In exchange for global rights to azer-cel for autoimmune diseases and indications outside of cancer, Precision will receive upfront and potential near-term economics valued at $17.5M. The upfront payment of $7.5 million will consist of cash and the purchase of 2,920,816 shares of Precision common stock by TG Therapeutics at a price of 77c per share, a 100% premium to the 30-day volume-weighted average price VWAP prior to purchase. Precision will also receive $2.5M within 12 months, as an equity investment in Precision's common stock at 100% premium to the then 30-day VWAP prior to purchase. Upon the achievement of certain near-term clinical milestones, Precision will receive an additional $7.5 M payment in cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the then current 30-day VWAP. Precision is eligible to receive up to $288 million in additional milestone payments based on the achievement of certain clinical, regulatory, and commercial milestones, in addition to high-single-digit to low-double-digit royalties on net sales...These transactions are expected to extend our runway and will fund continued development of our wholly owned in vivo gene editing programs. As a result of these two accretive partnerships, Precision has received or is eligible to receive $47M in upfront and potential near-term payments and has the potential to receive more than $900M in development, regulatory and commercial milestone payments," added Mr. Amoroso. Although it has not finalized its full financial results for the year ended December 31 , Precision expects to report that it had approximately $116 million in cash and cash equivalents as of December 31 . Upfront and potential near-term cash from azer-cel transactions, along with existing cash and cash equivalents, expected operational receipts, continued fiscal and operating discipline, availability of Precision's at-the-market ATM facility, and available credit are expected to extend Precision's cash runway into the first half of 2026 and through clinical phase 1 readouts for its wholly owned HBV and PMM programs. Precision will continue to evaluate potential partners for other assets from its allogeneic CAR T platform that are no longer being developed internally, including PBCAR19B stealth cell and BCMA targeting CAR T assets for multiple myeloma.

07:20 EST Wearable Devices announces commercial launch of Mudra Band at CES - Wearable Devices announces the commercial launch of its Mudra Band at the upcoming 2024 Consumer Electronic Show. Wearable Devices will be showcasing its latest innovations from January 9th to January 12th at the Las Vegas Convention Center, North Hall, Booth #8363 in Las Vegas, Nevada.

07:17 EST Canacol Energy says gas sales averaged 160 MMscfpd in December - Canacol Energy provides the following gas sales and drilling operations update. Realized contractual natural gas sales averaged 166 MMscfpd for the period of December 1 to December 20. Beginning December 21 2023 the Corporation performed two scheduled routine maintenance procedures on its Jobo processing plant which interrupted production levels until January 2, 2024, a period where gas demand is typically low due to the Holidays. As such, December realized contractual natural sales averaged 160 MMscfpd. The Corporation anticipates spudding the Clarinete 10 development well by the third week of January 2024, and anticipates that it will take approximately 3 weeks to drill and tie into permanent production.

07:16 EST Guardian Capital launches GuardBonds Funds - Guardian Capital announced the launch of a new suite of funds called GuardBonds. GuardBonds is new family of investment funds which combine key features of fund investing with buying individual bonds. Each of the mandates in the GuardBonds suite will provide exposure to a diversified portfolio of Canadian-dollar denominated investment grade bonds which have a defined maturity date that corresponds to a specific calendar year.

07:15 EST Novocure enrolls final patient in TRIDENT clinical trial - Novocure announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio concurrent with radiation therapy and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma.

07:13 EST Ashland announces organization changes to finance, strategy, portfolio - Ashland Inc. (NYSE: ASH), the global additives and specialty ingredients company today announced organization changes to its finance and strategy, mergers and acquisitions (M&A) and portfolio teams, effective immediately. Seth Mrozek, director of investor relations (IR), Ashland, becomes director, portfolio strategy, Ashland, reporting to Jim Minicucci, senior vice president strategy, M&A and portfolio management, Ashland. William Whitaker, vice president, treasury, Ashland, becomes vice president finance and director of investor relations, Ashland, reporting to Kevin Willis, chief financial officer, Ashland. Michael Coppola, finance director, personal care and specialty additives, becomes treasurer, Ashland, reporting to Willis. Michael Miragliotta, senior manager, financial planning and analysis becomes finance director, personal care and specialty additives, Ashland, reporting to Willis.

07:12 EST Inception Growth Acquisition announces additional contribution to trust account - Inception Growth Acquisition announced that on January 4, 2024, the Company deposited $100,000 into the Company's trust account in order to extend the period of time the Company has to complete a business combination for an additional one month period, from January 13, 2024 to February 13, 2024. The purpose of the extension is to provide additional time for the Company to complete a business combination.

07:10 EST GXO Logistics announces new customer Glossier - GXO Logistics announces that following its successful acquisition of PFSweb, it has won Glossier's direct-to-consumer fulfillment operations and will manage its business-to-business order fulfillment to their retail partners in the U.S.

07:09 EST Mobilicom secures new production-scale for its SkyHopper Pro Lite - Mobilicom announced it has received an initial production-scale order for its cybersecure SkyHopper Pro Lite datalinks from the Israel Aerospace Industries, a government-owned corporation and Israel's major aerospace and aviation manufacturer. Mobilicom's bi-directional software defined radio has been integrated into IAI's loitering drones based on a prior design win as the drones are entering commercial-scale production. This order is expected to be followed by larger purchases orders for Mobilicom's field-proven SkyHopper suite of products as the IAI's loitering drones are demonstrated, tested, and evaluated by additional potential customers worldwide, including the U.S. Department of Defense. "Drones are becoming more important in the battlefield, thus we are seeing increasing interest in our end-to-end solutions" stated Mobilicom CEO and Founder Oren Elkayam. "We've been working closely with IAI and our system has been integrated with the loitering drones which are now headed into production."

07:08 EST Tonix Pharmaceuticals presents additional data from TNX-203 SL - Tonix Pharmaceuticals announced the presentation of additional safety and tolerability data from RESILIENT, the second positive Phase 3 study evaluating TNX-102 SL for the management of fibromyalgia, at Biotech Showcase 2024 in San Francisco, January 8-10. As previously announced, RESILIENT met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo in participants with fibromyalgia. Statistically significant and clinically meaningful results were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms and function. Tonix plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2024 for TNX-102 SL for the management of fibromyalgia. RELIEF, the first Phase 3 trial of TNX-102 SL 5.6 mg in fibromyalgia, was completed in December 2020. It met its pre-specified primary endpoint of daily pain reduction compared to placebo and showed activity in key secondary endpoints.

07:06 EST Cyngn announces issuance of a new patent - Cyngn announced the issuance of a new patent, US-11,837,090-B2, for the company's autonomous vehicle and driving solutions. This new patent protects Cyngn's novel adaptive traffic rule-based decision making for autonomous driving that aims to optimize driving decisions in the presence of multiple rules or constraints imposed on an autonomous vehicle by its environment.

07:04 EST TG Therapeutics announces global license agreement with Precision BioSciences - TG Therapeutics (TGTX) announced that it has entered into an agreement with Precision BioSciences (DTIL) to acquire a worldwide license to Precision's Azercabtagene Zapreleucel, an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications. Azer-cel is an allogeneic CAR T program and the Company has near-term plans to evaluate the program in multiple autoimmune indications, with an investigational new drug (IND) filing targeted for mid-2024. Michael Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, "We are excited to expand our autoimmune portfolio and leverage our robust drug development and commercialization expertise in partnering with Precision on this CAR T program. We look forward to exploring azer-cel's potential to be a meaningful therapy for patients with various autoimmune disorders with a target IND filing mid-2024." Under the terms of the agreement, TG Therapeutics will receive exclusive worldwide rights to develop and commercialize azer-cel in non-oncology indications, and in exchange, Precision will receive upfront and potential near-term economics valued at $17.5 million. The upfront payment of $7.5 million will consist of cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the 30-day VWAP prior to purchase. Precision will also receive $2.5 million in deferred consideration due within 12 months as an equity investment in Precision's common stock at a 100% premium to the then 30-day VWAP prior to purchase. Upon the achievement of certain near-term clinical milestones, Precision will receive an additional $7.5 million payment, consisting of cash and the purchase of Precision common stock by TG at a 100% premium to the then current 30-day VWAP. Precision is also eligible to receive up to $288 million in additional payments based on the achievement of certain clinical, regulatory, and commercial milestones, in addition to high-single-digit to low double-digit royalties on net sales.

07:04 EST Concord Medical announces listing of subsidiary on HKSE - Concord Medical Services announced the listing of a minority stake of 39,420,200 H shares in Concord Healthcare Group Co., Ltd., its subsidiary, at an initial public offer price of HK$14.28 per H share on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code 2453.HK. Concord Healthcare's H shares began to trade on the HKSE on January 9. The company previously announced the submission of an application proof to list a minority stake in Concord Healthcare on the HKSE on June 1, 2022. The gross proceeds from the initial public offering of Concord Healthcare on the HKSE are approximately $72.2M. Concord Healthcare intends to apply approximately 59.4% of the net proceeds for repaying part of its interest-bearing bank borrowings, approximately 30.6% of the net proceeds for financing the construction of Shanghai Concord Cancer Center, and approximately 10.0% of the net proceeds for working capital and other general corporate purposes.

06:59 EST BioNTech provides strategic priorities and company update - BioNTech (BNTX) provided its FY24 revenue guidance as part of its outlined 2024 strategic priorities. Projects company revenues of approximately EUR3B for FY24, mainly driven by the COVID-19 vaccine franchise which is expected to remain profitable given the company's cost sharing structure with its partner Pfizer (PFE). BioNTech ended 2023 with approximately EUR 17.5B in cash, cash equivalents and security investments. The company plans to maintain a strong financial position and generate significant interest income in 2024. BioNTech expects to grow its topline again in 2025. In the outer years, the company projects revenues derived from both oncology and respiratory combination vaccine launches, which are subject to successful development and regulatory approval. Plans to have ten or more potentially registrational trials by the end of 2024 and is preparing to be commercial-ready by the end of 2025. BNT162b2 + BNT161 is an mRNA-based combination vaccine program against COVID-19 and influenza being developed in collaboration with Pfizer. Topline data from the Phase 1/2 trial demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains and that the safety profile of the candidates was consistent with the companies' COVID-19 vaccine. In oncology, the Company's pipeline continued to mature in 2023 with various programs advancing towards later stages of development. BioNTech's pipeline currently contains 11 ongoing Phase 2 and 3 trials. In 2024, BioNTech intends to accelerate the development of its portfolio of next-generation investigational medicines both as monotherapies and in combination with immunotherapy agents and other targeted therapies across a wide range of tumor types. BioNTech believes it is well positioned to have ten or more potentially registrational trials in areas of unmet medical need by the end of 2024 in advance of launching its first oncology products from 2026 onwards.

06:51 EST Endeavour Silver reports Q4, 2023 production numbers - Endeavour Silver reports full year 2023 production of 5,672,703 silver ounces and 37,858 gold oz, for silver equivalent production of 8.7M oz. Fourth quarter production was 1,396,315 silver oz and 9,440 gold oz for 2.2 million silver equivalent oz.

06:48 EST NOW Inc. to change corporate legal name to 'DNOW Inc.' on January 19 - NOW Inc. announced plans to change its corporate legal name to "DNOW Inc.," effective January 19. The company's ticker symbol, "DNOW", will remain unchanged. "The decision to harmonize our name and brand is underpinned by our commitment to elevate and distinguish DNOW as a solutions-based products and services provider. We are widely recognized as DNOW and the change of the Company's corporate legal name is a natural step in unifying our identity in the marketplace," stated David Cherechinsky, President and CEO of DNOW.

06:44 EST Uber says DOL rule 'does not materially change the law under which we operate' - CR Wooters, Head of Federal Affairs at Uber, issued the following statement on the U.S. Department of Labor's Worker Classification Rule: "Today, the U.S. Department of Labor issued a Final Rule to help determine whether a worker should be considered an employee or independent contractor under the Fair Labor Standards Act. This rule does not materially change the law under which we operate, and will not impact the classification of the over one million Americans who turn to Uber to earn money flexibly. Drivers across the country have made it overwhelmingly clear - in their comments on this rule and in survey after survey - that they do not want to lose the unique independence they enjoy. As this rule is implemented, we look forward to working with the Biden administration and making sure they continue to hear directly from drivers... As for Uber, we will continue pushing in states around the country for models that provide drivers with both flexibility and benefits, like what our CEO outlined in a New York Times op-ed and what is in our Working Together Priorities. Reference Link

06:38 EST MSC Industrial backs FY24 ADS view flat to up 5% - Backs FY24 adjusted operating margin view 12%-12.8%. Backs FY24 tax rate view 25%-25.5%. Gershwind concluded, "Looking ahead, despite a slower start to the fiscal year, I am encouraged as we continue building our market position, introducing strategic investments centered on reaccelerating our core customer base and implementing operational initiatives to drive productivity and expand margins. Together, this positions us to achieve our annual revenue growth and adjusted operating margin ranges in fiscal 2024."

06:27 EST Tarena to change ticker symbol - Tarena announced that it will change its ticker symbol on the Nasdaq from (TEDU) to (TCTM) effective on January 10 and that Ying Sun, the company's CEO, will lead the opening bell ceremony at the Nasdaq Capital Market alongside the Company's team on January 10, to celebrate the first day of trading on Nasdaq under the new ticker symbol of (TCTM).

06:15 EST Emeren acquires 10.76 MWh energy storage power portfolio from Kunneng - Emeren announced the successful acquisition of a 10.76 MWh energy storage power portfolio from Kunneng Smart Energy Service Group, which specializes in renewable energy industry, offering comprehensive solutions in solar, energy storage, power sales, and carbon asset management in China. Located in Zhejiang Province, the 10.76 MWh portfolio comprises six energy storage power stations, operates under the Energy Management Services agreements providing benefits to the customers based on energy arbitrage.

06:07 EST Elicio Therapeutics' ELI-002 shows antitumor efficacy in published Phase 1 trial - Elicio Therapeutics announced the publication of data from the Phase 1 - AMPLIFY-201 - study of ELI-002 2P in Nature Medicine. The paper details expanded and updated results originally presented at the 2023 American Society of Clinical Oncology Annual Meeting and the 2023 AACR Special Conference on Pancreatic Cancer. Publication highlights include: direct ex vivo mKRAS-specific T cell responses were observed in 21/25 patients. Tumor biomarker responses were observed in 21/25 patients - 84% - and biomarker clearance in 6/25 patients, as determined by tumor-informed circulating tumor DNA. At 8.5 months median follow-up the median RFS of the 25-patient cohort was 16.33 months. Efficacy correlated with T cell response: median tumor biomarker reduction was -76.0% compared to -10.2% in above versus below median T cell responders, respectively. Median RFS was not reached compared to 4.01 months in above versus below median T cell responders, respectively. Patients with greater than median T cell response had an 86% reduction in the risk of progression or death. The association of RFS with T cell response was not correlated to baseline prognostic variables. RFS was shorter in patients who began treatment with a low absolute lymphocyte count. No safety concerns were identified, and no dose limiting toxicities and no greater than or equal to grade 3 treatment related adverse events were observed.

06:04 EST CareTrust REIT acquires Southern California assisted living facility - CareTrust REIT announced that it has acquired The Villas at San Bernardino, a 78-unit assisted living and memory care facility located in San Bernardino, California. In connection with its acquisition of the facility, CareTrust and a third-party regional healthcare real estate investor entered into a joint venture arrangement under which CareTrust provided a combined common equity and preferred equity investment amount totaling $10.7M. CareTrust is the managing member of the joint venture entity. CareTrust's initial contractual yield on its combined preferred and common equity investments in the joint venture is approximately 9.3%. The facility will be operated by Oxford Health Group, a new operator relationship for CareTrust. Oxford is a midsize California seniors housing operator that focuses on strategically integrating healthcare services into its communities, allowing higher acuity residents to further age in the community setting. Oxford and the joint venture landlord entered into a new, triple-net lease agreement that provides for 2% fixed annual rent escalators, a 10-year initial term, and four, 5-year extension options.

06:02 EST Embecta announces FDA 510(k) submission for insulin patch pump - Embecta announced that it has submitted a 510(k) premarket filing to the U.S. FDA for a proprietary disposable insulin delivery system.

05:59 EST GSK enters agreement to acquire Aiolos Bio; deal includes $1B upfront payment - GSK plc and Aiolos Bio, Inc. announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1B upfront payment and up to $400M in certain success-based regulatory milestone payments. In addition, GSK will also be responsible for success-based milestone payments as well as tiered royalties owed to Hengrui. The acquisition provides GSK with access to Aiolos' AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma, with potential for additional indications including chronic rhinosinusitis with nasal polyps, GSK said in a statement. This transaction is subject to customary conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Act in the US. Tony Wood, Chief Scientific Officer, GSK, said: "We have a proud heritage and deep development expertise in respiratory medicines, especially addressing diseases driven by IL-5 with high levels of eosinophils or high T2 inflammation. Adding AIO-001, a potentially best-in-class medicine targeting the TSLP pathway, could expand the reach of our current respiratory biologics portfolio, including to the 40% of severe asthma patients with low T2 inflammation where treatment options are still needed." Reference Link

05:52 EST AbbVie launches Produodopa in European Union - AbbVie announced the launch of Produodopa in the European Union for the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia, and when available combinations of Parkinson's medicinal products have not given satisfactory results.

05:24 EST TH International opens tenth Popeyes store in Shanghai - TH International announced the grand opening of its tenth Popeyes store in Shanghai. In March, Tims China acquired the exclusive rights to operate and franchise Popeyes in mainland China and Macau. Since then, Tims China has repositioned the Popeyes brand for the Chinese market and has sold over 150,000 pieces of its original American crispy chicken. Looking ahead, Popeyes is set to expand across China, with plans to open 500 more stores in the next five years and 1,700 stores over the next decade.